Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bispecific antibody drug conjugates - Zymeworks

Next Previous
Drug Profile

Research programme: bispecific antibody drug conjugates - Zymeworks

Alternative Names: Biparatopic HER2 antibody; ZW 33

Latest Information Update: 28 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zymeworks
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Gastric cancer; Ovarian cancer

Most Recent Events

  • 28 Mar 2022 No recent reports of development identified for preclinical development in Ovarian-cancer in Canada
  • 28 Feb 2020 No recent reports of development identified for preclinical development in Breast-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV)
  • 06 Nov 2018 Zymeworks plans a phase I trial for ZW 49 in early 2019
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top